Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gabapentin is an anticonvulsant medication and a gamma-aminobutyric acid (GABA) analogue primarily used to treat neuropathic pain and partial seizures in epilepsy. It is also approved for postherpetic neuralgia (nerve pain after shingles) and moderate-to-severe restless legs syndrome. Gabapentin works by binding to the α2δ-1 subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters such as glutamate. This action decreases abnormal neuronal excitation associated with seizures and neuropathic pain. Gabapentin was first developed by Parke-Davis (a subsidiary of Pfizer), received FDA approval in 1993, and has been available as a generic since 2004[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gabapentin.